Cellid's AR Glasses Reference Design Featured in "Extended Reality: Visions of the Future" Exhibition at the Computer History Museum
Cellid Showcases AR Glasses Technology at Exhibition Exploring the Future of Wearable Computing TOKYO, Oct. 19, 2026 /PRNewswire/ -- Cellid Inc., a developer of displays and spatial recognition engines for next-generation augmented reality (AR)...
TUMI INTRODUCES GIFTS FOR THE JOURNEY THIS HOLIDAY SEASON
TUMI's Holiday Edit Celebrates the Art of Giving Through Craftsmanship and Considered Design NEW YORK, Oct. 19, 2026 /PRNewswire/ -- Today, international travel, lifestyle, and accessories brand TUMI debuts its holiday edit "Gifts for the Journey,"...
POMDOCTOR LIMITED Announces the Termination of Its ADR Program and Trade Class A Ordinary Shares on Nasdaq
GUANGZHOU, China, Oct. 19, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today announced that it...
Hyosung Chairman Hyun-Joon Cho Advances Bio-Based Materials Strategy with Commercial Bio-BDO Production in Vietnam
Chairman Cho positions bio-based materials as a core pillar of Hyosung's long-term growth Integrated production network connects sugarcane-derived raw materials to finished bio-based spandex US$1 billion investment supports 50,000 metric tons of...
Transcenta Therapeutics Announces Appointment of Ms. Jennie Ma as Chief Financial Officer
SUZHOU, China and PRINCETON, N.J., Oct. 19, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628) today announced that its Board of Directors has approved the appointment of Ms. Jennie Ma as Chief Financial Officer (CFO) of the Company. In this...
Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") and its partner Summit Therapeutics Inc. jointly announced an international multicenter Phase II clinical study (SMT112-216 / AK112-216 / NCT07877194). Built...
OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors
— New Studies Expand Cesalatamig into Biomarker-driven Precision Immuno-oncology Strategies — Cesalatamig is Also Being Evaluated in Ongoing Phase 2 Studies in the United States and in China ROCKVILLE, Md. , Oct. 19, 2026 /PRNewswire/ -- OncoC4...
Julia Gillard joins Hakluyt's International Advisory Board
LONDON, Oct. 19, 2026 /PRNewswire/ -- Hakluyt, the global strategic advisory firm for businesses and investors, is delighted to announce the appointment of The Honourable Julia Gillard AC, former prime minister of Australia and current chair of...